US20170192025A1 - Methods of monitoring adherence to lurasidone therapy - Google Patents

Methods of monitoring adherence to lurasidone therapy Download PDF

Info

Publication number
US20170192025A1
US20170192025A1 US15/469,021 US201715469021A US2017192025A1 US 20170192025 A1 US20170192025 A1 US 20170192025A1 US 201715469021 A US201715469021 A US 201715469021A US 2017192025 A1 US2017192025 A1 US 2017192025A1
Authority
US
United States
Prior art keywords
lurasidone
subject
circumflex over
therapy
fluid sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/469,021
Inventor
Jeffrey Enders
Erin Strickland
Gregory L. McIntire
Ayodele Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ameritox LLC
Original Assignee
Ameritox LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ameritox LLC filed Critical Ameritox LLC
Priority to US15/469,021 priority Critical patent/US20170192025A1/en
Publication of US20170192025A1 publication Critical patent/US20170192025A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present disclosure provides methods for monitoring subject (e.g., patient) adherence to lurasidone therapy, for example as a component of treating a subject for a mental health disorder such as schizophrenia.
  • Lurasidone (Latuda®) is an atypical antipsychotic prescribed for the treatment of acute symptoms of schizophrenia. Drug adherence has been shown to be particularly low in patients with schizophrenia. Urine drug testing has been employed by behavioral health clinicians to monitor patient compliance through analysis of drugs and their major metabolites. Typically, adherence to lurasidone therapy is monitored by evaluating levels of lurasidone and one of its plasma metabolites, M11 (2- ⁇ (3,5-Dioxo-4-azatricyclo[5.2.1.0 2,6 ]dec-4-yl)methyl ⁇ cyclohexanecarboxylic acid) (see Table 1 for structure). However, these molecules are present in only low levels after dosing, thus false negative monitoring results are common.
  • Such false negative reports can improperly induce a clinician (e.g., a physician or psychiatrist) to alter a compliant subject's lurasidone therapeutic regimen when no alteration is warranted.
  • a clinician e.g., a physician or psychiatrist
  • Improved methods for assessing and monitoring a subject's adherence to lurasidone therapy are needed.
  • the present disclosure provides methods for monitoring patient adherence to lurasidone therapy, for example as a component of treating a subject for a mental health disorder such as schizophrenia.
  • the present disclosure provides a method for monitoring lurasidone therapy in a subject who has been prescribed lurasidone therapy, the method comprising: obtaining a fluid sample from a subject who has been prescribed lurasidone therapy, analyzing the fluid sample for the presence of M8/M9, M21, and M22, and identifying the subject as adherent to the prescribed lurasidone therapy if the fluid sample contains M8/M9, M21, or M22 above a threshold level but non-adherent if the fluid sample contains no M8/M9, M21, or M22 or an amount of M8/M9, M21, or M22 below a threshold level.
  • the present disclosure provides a method of evaluating compliance with lurasidone therapy in a subject, the method comprising obtaining a fluid sample (e.g., urine) from the subject, analyzing the fluid sample for presence or absence of an analyte, and identifying the subject as compliant if the analyte is present in the fluid sample.
  • a fluid sample e.g., urine
  • FIG. 1 shows the MS/MS spectra of M8/M9 metabolite of lurasidone.
  • Lurasidone (Latuda®) is an atypical antipsychotic prescribed for the treatment of acute symptoms of schizophrenia. Lurasidone has a molecular weight of 492.6 g/mol, and empirical formula of C 28 H 36 N 4 O 2 S, a pK a of 7.6, a log P of 5.9, a CAS number of 367514-87-2, a mass-to-charge ratio (m/z) of 493.6 when ionized with addition of a proton (ESI MS), and has a formula chosen from the stereoisomeric Formulas (I) and (II) shown below:
  • Lurasidone is commercially available as 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg tablets and is typically prescribed or administered at 40 or 80 mg per day. It is absorbed after oral administration with a bioavailability of 9 to 19%. Dosing is designed to be with food as this can increase the bioavailability by 100%. The mean elimination half-life is 18 hours. Steady state serum concentrations for Lurasidone are typically achieved after 7 days of dosing.
  • Lurasidone is metabolized in the liver primarily by CYP3A4. Metabolism includes oxidative N-dealkylation, hydroxylation of the norbane ring, S-oxidation, and reductive cleavage of the isothiazole ring followed by S-methylation. Nearly two dozen metabolites of lurasidone have been previously identified. Select metabolites of lurasidone are shown in Table 1 below.
  • M11 and M5 are not biologically active, but have been reported to be “major” metabolites (e.g., defined by ⁇ 10%, total drug exposure).
  • Metabolites ID-14283 (M8) and ID-14326 (M9) are known to be biologically active, but not considered “major” metabolites.
  • Lurasidone metabolite designated M8 and its isomer M9 are a result of the hydroxylation of the norbornane ring and are both the only known active metabolites of lurasidone.
  • Previous studies using radiolabelled lurasidone e.g., [carbonyl- 14 C]lurasidone
  • M8 ID-14283
  • M9 ID-14326
  • Lurasidone metabolite designated M21 is the result of reductive opening of the isothiazole ring followed by methylation of the free sulfur.
  • radiolabelled lurasidone e.g., [carbonyl- 14 C]lurasidone
  • M21 a circulating metabolite in serum of any of the animal models.
  • other metabolites that have been further modified from the original M21 compound N-dealkyl-M21, Keto-N-dealkyl M21, and Trioxy-M21 have been identified in the majority of the animal models in unspecified low amounts in serum, including humans.
  • Lurasidone metabolite designated M22 is the result of reductive opening of the isothiazole ring followed by methylation of the free sulfur and hydroxylation of the norborane ring.
  • radiolabelled lurasidone e.g., [carbonyl- 14 C]lurasidone
  • M22 was present in humans at less than 10% of the total drug-related exposure, and was not detected in any amount in other animal models, such as rabbits or monkeys. Previous studies do not identify M22 as a primary circulating metabolite in mice, rats, rabbits, dogs, monkeys or humans.
  • Urine drug testing has been employed by behavioral health clinicians to monitor patient compliance through analysis of drugs and their major metabolites.
  • the present disclosure provides a method for monitoring lurasidone therapy in a subject.
  • the method comprises obtaining a fluid sample from a subject who has been prescribed lurasidone therapy, analyzing the fluid sample for the presence of M8/M9, M21, and M22, and identifying the subject as adherent to the prescribed lurasidone therapy if the fluid sample contains M8/M9, M21, and/or M22 above a threshold level but non-adherent if the fluid sample contains no M8/M9, M21, and/or M22 or an amount of M8/M9, M21, and/or M22 below a threshold level.
  • the method further comprises identifying the subject as having been prescribed lurasidone therapy. In some embodiments, the method further comprises counseling the subject on dangers of non-adherence to lurasidone therapy if the subject is identified as non-adherent. In some embodiments, the threshold level is a minimum detectable amount of M8/M9, M21, and/or M22.
  • the threshold level is about 5 ng/mL to about 500 ng/mL, for example about 5 ng/mL, about 10 ng/mL, about 15 ng/mL, about 20 ng/mL, about 25 ng/mL, about 30 ng/mL, about 35 ng/mL, about 40 ng/mL, about 45 ng/mL, about 50 ng/mL, about 55 ng/mL, about 60 ng/mL, about 65 ng/mL, about 70 ng/mL, about 75 ng/mL, about 80 ng/mL, about 85 ng/mL, about 90 ng/mL, about 95 ng/mL, about 100 ng/mL, about 125 ng/mL, about 150 ng/mL, about 175 ng/mL, about 200 ng/mL, about 225 ng/mL, about 250 ng/mL, about 275 ng/mL, about 300 ng/mL,
  • the present disclosure provides a method of evaluating compliance with lurasidone therapy in a subject.
  • the method comprises obtaining a fluid sample from a subject who has been prescribed lurasidone therapy, analyzing the fluid sample for presence or absence of an analyte, and identifying the subject as compliant if the analyte is present in the fluid sample.
  • the analyte comprises lurasidone and/or a lurasidone metabolite.
  • the analyte is selected from the group consisting of M5, M10, M11, M11 Glucuronide, ID-20221, ID-20222, M8/M9, M21, and M22, or a combination thereof. In some embodiments, the analyte comprises M8/M9, M21, and/or M22. In some embodiments, the analyte is considered present in the fluid sample if the analyte is detected above a threshold value. In some embodiments, the threshold value is about 50 ng/mL. In some embodiments, the threshold value is about 5 ng/mL. In some embodiments, the method further comprises identifying the subject as having been prescribed lurasidone therapy.
  • two or more drug metabolites are determined, a ratio of one metabolite to at least one other metabolite is calculated, and a risk of the subject's noncompliance is determined if the ratio falls outside confidence intervals or mathematically transformed and normalized range of that ratio for the daily dose of the drug.
  • one metabolite is the parent drug originally dosed to the patient.
  • the ratio is of one metabolite to the sum of all metabolites.
  • Urine samples of normally metabolizing human subjects who were known to be taking chronic doses of lurasidone were tested for the presence of lurasidone and eleven metabolites (excluding isomeric metabolites). Each patient sample was analyzed twice to ensure accuracy. Due to the high probability for false identification of isobars, MS/MS data was collected and selectively looked at to add confidence to the identification. In particular, it was determined that a peak that could have arisen from any of M8, M9 or M10 was actually M8/M9 (stereoisomers) because of the presence of a peak at 182 m/z indicating a hydroxylated norborane ring.
  • metabolites M8/M9, M21, and M22 were unexpectedly present in detectable quantities in each test of each subject's urine sample. This was unexpected because M8/M9, M21, and M22 are reported to be only minor metabolites detectable in plasma in only a few species. Notably, reliance on the presence of any metabolite other than M8/M9, M21, or M22 in urine would have generated false negative test results for at least half of the 12 subjects listed in Table 2. While lurasidone was detected in the majority of the samples, it was typically not one of the three most abundant peaks in the sample and was unobserved in one sample. Therefore, the monitoring of the M8/M9, M21, and M22 metabolites can be used to reduce the possibility of false negatives.
  • M8/M9, M21, or M22 metabolites only ⁇ 88% were determined to be positive solely by the parent compound lurasidone.
  • use of M8/M9, M21, and M22 as a urine biomarker at this low dose adds value to compliance monitoring for Latuda®.
  • M8/M9, M21, or M22 metabolites only ⁇ 92% were determined to be positive solely by the parent compound lurasidone.
  • use of M8/M9, M21, and M22 as a urine biomarker at this dose adds value to compliance monitoring for Latuda®.
  • M8/M9, M21, or M22 metabolites only ⁇ 93% were determined to be positive solely by the parent compound lurasidone.
  • use of M8/M9, M21, and M22 as a urine biomarker at this dose adds value to compliance monitoring for Latuda®.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides methods for monitoring subject (e.g., patient) adherence to lurasidone therapy, for example as a component of treating a subject for a mental health disorder such as schizophrenia.

Description

    PRIORITY CLAIM
  • This application is a continuation of U.S. patent application Ser. No. 14/567,935 filed Dec. 11, 2014, which claims priority to U.S. Provisional Patent Application Ser. No. 61/915,070, filed Dec. 12, 2013, and to U.S. Provisional Patent Application Ser. No. 62/035,821, filed Aug. 11, 2014, the entire contents of each of which are incorporated herein by reference and relied upon.
    • TECHNICAL FIELD
  • The present disclosure provides methods for monitoring subject (e.g., patient) adherence to lurasidone therapy, for example as a component of treating a subject for a mental health disorder such as schizophrenia.
    • BACKGROUND
  • Lurasidone (Latuda®) is an atypical antipsychotic prescribed for the treatment of acute symptoms of schizophrenia. Drug adherence has been shown to be particularly low in patients with schizophrenia. Urine drug testing has been employed by behavioral health clinicians to monitor patient compliance through analysis of drugs and their major metabolites. Typically, adherence to lurasidone therapy is monitored by evaluating levels of lurasidone and one of its plasma metabolites, M11 (2-{(3,5-Dioxo-4-azatricyclo[5.2.1.02,6]dec-4-yl)methyl}cyclohexanecarboxylic acid) (see Table 1 for structure). However, these molecules are present in only low levels after dosing, thus false negative monitoring results are common. Such false negative reports can improperly induce a clinician (e.g., a physician or psychiatrist) to alter a compliant subject's lurasidone therapeutic regimen when no alteration is warranted. Improved methods for assessing and monitoring a subject's adherence to lurasidone therapy are needed.
    • SUMMARY
  • The present disclosure provides methods for monitoring patient adherence to lurasidone therapy, for example as a component of treating a subject for a mental health disorder such as schizophrenia.
  • In one embodiment, the present disclosure provides a method for monitoring lurasidone therapy in a subject who has been prescribed lurasidone therapy, the method comprising: obtaining a fluid sample from a subject who has been prescribed lurasidone therapy, analyzing the fluid sample for the presence of M8/M9, M21, and M22, and identifying the subject as adherent to the prescribed lurasidone therapy if the fluid sample contains M8/M9, M21, or M22 above a threshold level but non-adherent if the fluid sample contains no M8/M9, M21, or M22 or an amount of M8/M9, M21, or M22 below a threshold level.
  • In another embodiment, the present disclosure provides a method of evaluating compliance with lurasidone therapy in a subject, the method comprising obtaining a fluid sample (e.g., urine) from the subject, analyzing the fluid sample for presence or absence of an analyte, and identifying the subject as compliant if the analyte is present in the fluid sample.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 shows the MS/MS spectra of M8/M9 metabolite of lurasidone.
    •  DETAILED DESCRIPTION
  • While the present invention is capable of being embodied in various forms, the description below of several embodiments is made with the understanding that the present disclosure is to be considered as an exemplification of the invention, and is not intended to limit the invention to the specific embodiments illustrated. Headings are provided for convenience only and are not to be construed to limit the invention in any manner. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.
  • The use of numerical values in the various quantitative values specified in this application, unless expressly indicated otherwise, are stated as approximations as though the minimum and maximum values within the stated ranges were both preceded by the word “about.” Also, the disclosure of ranges is intended as a continuous range including every value between the minimum and maximum values recited as well as any ranges that can be formed by such values. Also disclosed herein are any and all ratios (and ranges of any such ratios) that can be formed by dividing a disclosed numeric value into any other disclosed numeric value. Accordingly, the skilled person will appreciate that many such ratios, ranges, and ranges of ratios can be unambiguously derived from the numerical values presented herein and in all instances such ratios, ranges, and ranges of ratios represent various embodiments of the present invention.
  • Lurasidone (Latuda®) is an atypical antipsychotic prescribed for the treatment of acute symptoms of schizophrenia. Lurasidone has a molecular weight of 492.6 g/mol, and empirical formula of C28H36N4O2S, a pKa of 7.6, a log P of 5.9, a CAS number of 367514-87-2, a mass-to-charge ratio (m/z) of 493.6 when ionized with addition of a proton (ESI MS), and has a formula chosen from the stereoisomeric Formulas (I) and (II) shown below:
  • Figure US20170192025A1-20170706-C00001
  • Lurasidone is commercially available as 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg tablets and is typically prescribed or administered at 40 or 80 mg per day. It is absorbed after oral administration with a bioavailability of 9 to 19%. Dosing is designed to be with food as this can increase the bioavailability by 100%. The mean elimination half-life is 18 hours. Steady state serum concentrations for Lurasidone are typically achieved after 7 days of dosing.
  • Lurasidone is metabolized in the liver primarily by CYP3A4. Metabolism includes oxidative N-dealkylation, hydroxylation of the norbane ring, S-oxidation, and reductive cleavage of the isothiazole ring followed by S-methylation. Nearly two dozen metabolites of lurasidone have been previously identified. Select metabolites of lurasidone are shown in Table 1 below.
  • TABLE 1
    Select Metabolites of Lurasidone.
    Figure US20170192025A1-20170706-C00002
    Figure US20170192025A1-20170706-C00003
    Figure US20170192025A1-20170706-C00004
    Figure US20170192025A1-20170706-C00005
    Figure US20170192025A1-20170706-C00006
    Figure US20170192025A1-20170706-C00007
    Figure US20170192025A1-20170706-C00008
    Figure US20170192025A1-20170706-C00009
    Figure US20170192025A1-20170706-C00010
    Figure US20170192025A1-20170706-C00011
  • Among the various known lurasidone metabolites, M11 and M5 are not biologically active, but have been reported to be “major” metabolites (e.g., defined by ≧10%, total drug exposure). Metabolites ID-14283 (M8) and ID-14326 (M9) are known to be biologically active, but not considered “major” metabolites.
  • Lurasidone metabolite designated M8 and its isomer M9 (C28H36N4O3S) are a result of the hydroxylation of the norbornane ring and are both the only known active metabolites of lurasidone. Previous studies using radiolabelled lurasidone (e.g., [carbonyl-14C]lurasidone) have identified M8 (ID-14283) as present in an unspecified low amount in serum of humans after (40 mg oral dosing) and in mice, rats, dogs, and monkeys after 10 mg/kg oral administration. Additionally, M9 (ID-14326) was also identified in rats and dogs, and was the more preferential metabolite in dogs over M8.
  • Lurasidone metabolite designated M21 (C29H40N4O2S) is the result of reductive opening of the isothiazole ring followed by methylation of the free sulfur. Previous studies using radiolabelled lurasidone (e.g., [carbonyl-14C]lurasidone) did not detect M21 as a circulating metabolite in serum of any of the animal models. However, other metabolites that have been further modified from the original M21 compound (N-dealkyl-M21, Keto-N-dealkyl M21, and Trioxy-M21) have been identified in the majority of the animal models in unspecified low amounts in serum, including humans.
  • Lurasidone metabolite designated M22 (C29H40N4O3S) is the result of reductive opening of the isothiazole ring followed by methylation of the free sulfur and hydroxylation of the norborane ring. Previous studies using radiolabelled lurasidone (e.g., [carbonyl-14C]lurasidone) have identified M22 as present in an unspecified low amount in serum of humans (after 40 mg oral dosing) and in mice, rats and dogs after 10 mg/kg oral administration. However, M22 was present in humans at less than 10% of the total drug-related exposure, and was not detected in any amount in other animal models, such as rabbits or monkeys. Previous studies do not identify M22 as a primary circulating metabolite in mice, rats, rabbits, dogs, monkeys or humans.
  • Drug adherence has been shown to be particularly low in patients with schizophrenia. Urine drug testing has been employed by behavioral health clinicians to monitor patient compliance through analysis of drugs and their major metabolites.
  • In one embodiment, the present disclosure provides a method for monitoring lurasidone therapy in a subject. In some embodiments, the method comprises obtaining a fluid sample from a subject who has been prescribed lurasidone therapy, analyzing the fluid sample for the presence of M8/M9, M21, and M22, and identifying the subject as adherent to the prescribed lurasidone therapy if the fluid sample contains M8/M9, M21, and/or M22 above a threshold level but non-adherent if the fluid sample contains no M8/M9, M21, and/or M22 or an amount of M8/M9, M21, and/or M22 below a threshold level. In some embodiments, the method further comprises identifying the subject as having been prescribed lurasidone therapy. In some embodiments, the method further comprises counseling the subject on dangers of non-adherence to lurasidone therapy if the subject is identified as non-adherent. In some embodiments, the threshold level is a minimum detectable amount of M8/M9, M21, and/or M22. In some embodiments, the threshold level is about 5 ng/mL to about 500 ng/mL, for example about 5 ng/mL, about 10 ng/mL, about 15 ng/mL, about 20 ng/mL, about 25 ng/mL, about 30 ng/mL, about 35 ng/mL, about 40 ng/mL, about 45 ng/mL, about 50 ng/mL, about 55 ng/mL, about 60 ng/mL, about 65 ng/mL, about 70 ng/mL, about 75 ng/mL, about 80 ng/mL, about 85 ng/mL, about 90 ng/mL, about 95 ng/mL, about 100 ng/mL, about 125 ng/mL, about 150 ng/mL, about 175 ng/mL, about 200 ng/mL, about 225 ng/mL, about 250 ng/mL, about 275 ng/mL, about 300 ng/mL, about 325 ng/mL, about 350 ng/mL, about 375 ng/mL, about 400 ng/mL, about 425 ng/mL, about 450 ng/mL, about 475 ng/mL, or about 500 ng/mL. In some embodiments, the threshold level is about 50 ng/mL. In some embodiments, the fluid sample is a urine sample.
  • In another embodiment, the present disclosure provides a method of evaluating compliance with lurasidone therapy in a subject. In some embodiments, the method comprises obtaining a fluid sample from a subject who has been prescribed lurasidone therapy, analyzing the fluid sample for presence or absence of an analyte, and identifying the subject as compliant if the analyte is present in the fluid sample. In some embodiments, the analyte comprises lurasidone and/or a lurasidone metabolite. In some embodiments, the analyte is selected from the group consisting of M5, M10, M11, M11 Glucuronide, ID-20221, ID-20222, M8/M9, M21, and M22, or a combination thereof. In some embodiments, the analyte comprises M8/M9, M21, and/or M22. In some embodiments, the analyte is considered present in the fluid sample if the analyte is detected above a threshold value. In some embodiments, the threshold value is about 50 ng/mL. In some embodiments, the threshold value is about 5 ng/mL. In some embodiments, the method further comprises identifying the subject as having been prescribed lurasidone therapy.
  • In some embodiments, two or more drug metabolites (e.g., primary, secondary, and/or tertiary metabolites) are determined, a ratio of one metabolite to at least one other metabolite is calculated, and a risk of the subject's noncompliance is determined if the ratio falls outside confidence intervals or mathematically transformed and normalized range of that ratio for the daily dose of the drug. In some embodiments, one metabolite is the parent drug originally dosed to the patient. In some embodiments, the ratio is of one metabolite to the sum of all metabolites.
    • EXAMPLES Example 1
  • Urine samples of normally metabolizing human subjects who were known to be taking chronic doses of lurasidone were tested for the presence of lurasidone and eleven metabolites (excluding isomeric metabolites). Each patient sample was analyzed twice to ensure accuracy. Due to the high probability for false identification of isobars, MS/MS data was collected and selectively looked at to add confidence to the identification. In particular, it was determined that a peak that could have arisen from any of M8, M9 or M10 was actually M8/M9 (stereoisomers) because of the presence of a peak at 182 m/z indicating a hydroxylated norborane ring. If the peak had been M10, there would have been a prominent peak at 166 m/z indicating an un-hydroxylated norborane ring and a peak at 152 m/z indicating an oxidation on the sulfur and neither peak was observed. The 182 m/z peak is highlighted in FIG. 1 (arrow) indicating that the species identified is M8/M9. It is also clear in this spectrum that there are not any apparent peaks between 140-170 m/z where the expected M10 fragments of 166 and 152 m/z would appear indicating that the M10 is not present at any significant amount. Due to the high mass accuracy and low mass error on the Quadrupole Time-of-Flight (Q-ToF) Mass Spectrometer, compounds that have similar mass to charge ratios (e.g., m/z), but different chemical formulas were differentiated with the searching algorithm (e.g., M8/M9 and M21).
  • In plasma, lurasidone has been reported to account for 12% of the total radioactivity post oral dosing, while ID-20219 (M11) represents 24% of the total radioactivity, and ID-20220 (M5) for at least 10% (e.g., about 11%) of the total radioactive dose in the plasma. Excretion studies in humans report that the drug is excreted with 80% in the feces and 9% recovered in the urine.
  • Surprisingly, neither metabolite ID-20220 (M5) nor metabolite ID-20219 (M11) were found to be excreted through human urine in detectable amounts. Instead, the identity of detectable lurasidone metabolites varies widely from subject to subject, as shown in Table 2 below. Only the eight most significant metabolites out of the eleven searched are presented in Table 2 for simplicity.
  • TABLE 2
    Lurasidone Metabolite Distribution in Human Urine
    Analyte
    Lurasidone M8/M9/M10 M11 M11 Gluc ID-20221 ID-20222 M22 M21 M4/M5/M6
    MW
    Subject ID Run 492.2559 508.2508 305.1627 481.1948 524.2457 540.2406 524.2821 508.2872 321.1576
    Subject 1 1 ✓{circumflex over ( )} ✓* ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )}*
    2 ✓{circumflex over ( )} ✓* ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )}*
    Subject 2 1 ✓* ✓{circumflex over ( )}* ✓{circumflex over ( )}* ✓{circumflex over ( )} ✓
    2 ✓* ✓{circumflex over ( )}* ✓{circumflex over ( )}* ✓{circumflex over ( )} ✓
    Subject 3 1 ✓{circumflex over ( )} ✓ ✓* ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )}*
    2 ✓{circumflex over ( )} ✓* ✓* ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )}
    Subject 4 1 ✓{circumflex over ( )}* ✓{circumflex over ( )}* ✓ ✓ ✓{circumflex over ( )}* ✓ ✓
    2 ✓{circumflex over ( )}* ✓{circumflex over ( )}* ✓ ✓{circumflex over ( )}* ✓ ✓
    Subject 5 1 ✓* ✓{circumflex over ( )}* ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )} ✓
    2 ✓* ✓{circumflex over ( )}* ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )} ✓
    Subject 6 1 ✓* ✓{circumflex over ( )} ✓ ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )}*
    2 ✓* ✓{circumflex over ( )} ✓ ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )}*
    Subject 7 1 ✓* ✓{circumflex over ( )}* ✓ ✓ ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )}
    2 ✓* ✓{circumflex over ( )}* ✓ ✓ ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )}
    Subject 8 1 ✓* ✓{circumflex over ( )}* ✓ ✓ ✓{circumflex over ( )} ✓{circumflex over ( )}*
    2 ✓* ✓{circumflex over ( )}* ✓ ✓ ✓{circumflex over ( )} ✓{circumflex over ( )}*
    Subject 9 1 ✓{circumflex over ( )} ✓ ✓* ✓{circumflex over ( )}* ✓{circumflex over ( )}*
    2 ✓{circumflex over ( )} ✓ ✓* ✓{circumflex over ( )}* ✓{circumflex over ( )}*
    Subject 10 1 ✓ ✓{circumflex over ( )} ✓ ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )}* ✓*
    2 ✓ ✓{circumflex over ( )} ✓ ✓* ✓{circumflex over ( )} ✓{circumflex over ( )}* ✓*
    Subject 12 1 ✓{circumflex over ( )} ✓* ✓{circumflex over ( )}* ✓{circumflex over ( )}*
    2 ✓{circumflex over ( )} ✓* ✓{circumflex over ( )}* ✓{circumflex over ( )}*
    Subject 13 1 ✓ ✓{circumflex over ( )}* ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )}* ✓
    2 ✓ ✓{circumflex over ( )}* ✓ ✓{circumflex over ( )}* ✓{circumflex over ( )}* ✓
    ✓ Indicates that the compound was successfully identified in a qualitative manner;
    “{circumflex over ( )}” Indicates that the noted compound was one of the three most abundant compounds identified in that particular sample;
    “*” Indicates that the noted compound was one of the three most confidently identified in that particular sample and run.
  • As shown above, metabolites M8/M9, M21, and M22 were unexpectedly present in detectable quantities in each test of each subject's urine sample. This was unexpected because M8/M9, M21, and M22 are reported to be only minor metabolites detectable in plasma in only a few species. Notably, reliance on the presence of any metabolite other than M8/M9, M21, or M22 in urine would have generated false negative test results for at least half of the 12 subjects listed in Table 2. While lurasidone was detected in the majority of the samples, it was typically not one of the three most abundant peaks in the sample and was unobserved in one sample. Therefore, the monitoring of the M8/M9, M21, and M22 metabolites can be used to reduce the possibility of false negatives.
    • Example 2
  • The urine of 20 patients who were prescribed 20 mg of Latuda® (lurasidone) was tested for compliance over 5 days (Table 3). The preponderance of M8/M9, M21, and M22 in the urine as the major metabolic urine compounds is shown in Table 3. Assuming 60 opportunities to determine the patient to be either positive or negative for Latuda® dosing, the use of M8/M9, M21, and M22 resulted in 100% correct identification of those taking the prescribed medicine. The data in Table 4 demonstrate the “normal” nature of the sample validity criteria (i.e., pH, specific gravity, and creatinine). Without the M8/M9, M21, or M22 metabolites, only ˜88% were determined to be positive solely by the parent compound lurasidone. Thus, use of M8/M9, M21, and M22 as a urine biomarker at this low dose adds value to compliance monitoring for Latuda®.
  • TABLE 3
    Test Results from Patients Prescribed 20 mg/day Latuda ® (all metabolite data reported in ng/mL).
    S-Methyl
    Hydroxy- S-Methyl Hydroxy
    Creatinine Specific Lurasidone Lurasidone Lurasidone
    Subject Day pH (mg/dL) Gravity Lurasidone (M8/M9) (M21) (M22)
    A 1 7.7 76.0 1.007 12.0 29.6 32.6 42.6
    4 7.5 163.0 1.011 149.0 456.1 240.9 76.8
    5 9.0‡ 134.7 1.003 9.6 21.9 21.0 40.2
    B 1 8.6 78.0 1.005 9.7 12.2 22.3 18.6
    4 5.4 121.0 1.014 14.3 15.9 104.1 33.5
    5 8.4 110.6 1.006 8.8 24.7 127.9 108.7
    C 1 5.4 287.5 1.022 12.7 38.2 201.6 153.0
    4 5.3 300.3 1.022 18.9 53.8 355.2 256.3
    5 6.5 178.3 1.014 13.2 31.4 142.1 109.1
    D 1 6.2 193.4 1.017 9.0 11.8 118.8 57.7
    4 5.6 74.2 1.009 4.8** 18.2 113.4 60.3
    5 5.6 206.9 1.017 24.4 76.0 324.0 157.3
    E 1 7.1 95.3 1.008 33.1 70.0 88.8 43.7
    4 6.8 39.0 1.004 14.0 41.9 37.2 22.6
    5 6.3 62.1 1.007 26.2 47.0 51.9 24.4
    F 1 6.6 225.4 1.018 24.6 82.1 81.3 46.8
    4 7.9 56.6 1.005 5.7 10.9 25.2 7.3
    5 5.5 129.8 1.016 20.3 29.6 66.7 20.4
    G 1 6.2 22.7 1.003 6.9 8.3 44.0 7.8
    4 5.5 12.1‡ 1.002 4.7* ** 6.1 17.5 4.1**
    5 5.1 13.6‡ 1.003 6.5 6.7 25.1 5.3
    H 1 6.9 171.1 1.013 6.0 6.3 53.1 16.4
    4 5.0 71.4 1.008 7.0 11.0 57.1 13.3
    5 7.1 151.0 1.009 6.6 85.7 138.4 39.5
    I 1 5.3 24.0 1.003 4.4* ** 3.7* ** 35.3 6.1
    4 5.9 27.5 1.003 2.9* ** 3.3* ** 32.5 4.4**
    5 4.7 22.2 1.003 6.0 7.1 29.4 4.1**
    J 1 6.4 71.8 1.005 9.1 17.0 53.4 16.0
    4 5.0 247.5 1.018 31.3 63.7 245.2 61.0
    5 5.7 120.0 1.009 18.6 38.9 134.2 34.7
    K 1 8.8 188.8 0.982‡ 9.1 184.5 311.8 342.0
    4 8.4 65.2 0.993‡ 13.0 75.2 163.1 91.5
    5 8.4 89.0 0.993‡ 12.1 97.5 221.7 107.9
    L 1 7.3 72.6 1.006 10.1 17.3 11.0 16.2
    4 7.8 105.3 1.004 7.3 1.2** 15.8 20.9
    5 8.0 87.1 1.006 13.6 32.2 21.7 27.8
    N 1 6.6 210.0 1.002 5.7 11.0 14.9 8.4
    4 6.5 113.1 1.009 24.3 38.9 111.0 51.1
    5 6.5 13.3‡ 1.001‡ 5.4 4.3** 10.7 5.0
    O 1 7.1 94.7 1.010 7.8 8.6 49.5 19.0
    4 7.8 46.5 1.005 4.3** 2.8** 15.6 6.9
    5 5.7 119.3 1.010 10.2 18.1 53.8 16.2
    P 1 8.1 153.8 1.008 12.9 41.4 92.2 46.0
    4 8.2 196.9 1.005 12.5 89.8 223.0 157.2
    5 8.6 293.6 1.003 11.0 88.2 173.7 213.0
    Q 1 6.7 112.9 1.011 25.8 80.2 94.9 37.9
    4 6.8 88.2 1.013 17.5 20.1 38.2 14.1
    5 5.8 53.0 1.008 12.4 13.4 26.1 11.8
    R 1 6.9 40.0 1.004 13.8 35.5 60.6 33.8
    4 7.5 41.0 1.004 7.0 17.3 33.3 24.6
    5 8.6 26.1 1.001‡ 5.2 19.7 27.8 17.5
    YY 1 7.3 30.0 1.005 3.2** 12.8* 29.5 27.3
    4 6.6 87.8 1.010 5.8 21.0 110.7 88.2
    5 6.6 55.3 1.006 4.7** 10.7 61.5 47.4
    CCC 1 5.8 113.4 1.012 83.1 181.3 637.9 365.9
    4 5.4 96.1 1.015 29.1 26.7 208.9 133.1
    5 5.7 89.6 1.014 23.2 21.1 152.3 96.7
    III 1 5.4 34.9 1.001‡ 33.4 89.7 107.7 59.2
    4 5.4 25.8 1.009 8.0 7.4 41.7 28.8
    5 6.1 141.6 1.010 10.4 15.6 149.7 117.1
    ‡Indicates that the specimen validity criteria marked was not acceptable.
    *Indicates that the ion ratio criteria were not met.
    **Indicates that the value is below our established LOD/LOQ of 5 ng/mL and should be interpreted as a negative result.
  • TABLE 4
    Sample Validity and Urine Results Summary at 20 mg/day
    (all metabolite data reported in ng/mL).
    S-Methyl
    Hydroxy- S-Methyl Hydroxy
    Creatinine Specific Lurasidone Lurasidone Lurasidone
    pH (mg/dL) Gravity Lurasidone (M8/M9) (M21) (M22)
    Average 6.52 113.61 1.01 18.38 43.67 102.39 60.97
    Standard 1.03 72.35 0.01 23.16 68.39 108.52 70.37
    Deviation
    n 53
    Maximum 8.60 300.30 1.02 149.00 456.10 637.90 365.90
    Value
    Median 6.50 95.30 1.01 12.45 22.90 60.60 34.25
    Value
    Minimum 4.70 22.20 1.00 5.70 6.10 11.00 5.30
    Value
  • Samples that were deemed invalid based on pH and/or specific gravity (n=7) were not included in calculations. Any drug/metabolite concentration that was less than the LOD/LOQ (5 ng/m L) as noted in Table 3 was also excluded from the calculations.
    • Example 3
  • The urine of 12 patients who were prescribed 40 mg of Latuda® (lurasidone) was tested for compliance over 5 days (Table 5). The preponderance of M8/M9, M21, and M22 in the urine as the major metabolic urine compounds is shown in Table 5. Assuming 36 opportunities to determine the patient to be either positive or negative for Latuda® dosing, the use of M8/M9, M21, and M22 resulted in 100% correct identification of those taking the prescribed medicine. The data in Table 6 demonstrate the “normal” nature of the sample validity criteria (i.e., pH, specific gravity, and creatinine). Without the M8/M9, M21, or M22 metabolites, only ˜92% were determined to be positive solely by the parent compound lurasidone. Thus, use of M8/M9, M21, and M22 as a urine biomarker at this dose adds value to compliance monitoring for Latuda®.
  • TABLE 5
    Test Results from Patients Prescribed 40 mg/day Latuda ® (all metabolite data reported in ng/mL).
    S-Methyl
    Hydroxy- S-Methyl Hydroxy
    Creatinine Specific Lurasidone Lurasidone Lurasidone
    Subject Day pH (mg/dL) Gravity Lurasidone (M8/M9) (M21) (M22)
    S 1 8.8 182.8 0.993‡ 77.1 248.1 685.1 269.1
    4 9.2‡ 92.4 0.996‡ 21.7 68.3 176.6 11.2
    5 9.0‡ 63.5 0.999‡ 37.9 89.2 173.7 75.6
    T 1 7.2 100.8 1.011 30.5 42.2 129.0 35.8
    4 8.3 148.2 1.011 25.6 60.5 313.4 136.3
    5 7.6 274.8 1.014 37.9 66.3 443.7 186.3
    U 1 6.0 99.5 1.006 31.9 25.1 131.4 86.4
    4 5.2 264.6 1.015 70.7 74.4 559.0 424.1
    5 5.1 162.3 1.014 60.0 57.7 283.7 170.6
    V 1 5.9 103.4 1.013 63.9 131.2 571.3 470.9
    4 5.4 305.7 1.024 69.3 163.5 1282.8 1099.2
    5 5.7 58.2 1.006 33.4 48.4 290.6 241.1
    W 1 7.3 292.8 1.015 25.8 39.7 640.5 346.5
    4 6.7 94.3 1.013 26.4 24.1 252.6 198.1
    5 6.9 229.8 1.012 40.1 67.7 823.1 547.3
    X 1 8.0 69.4 1.008 4.4** 5.6 39.4 35.3
    4 6.9 15.0‡ 1.005 1.0** 2.7** 31.8 11.6
    5 8.4 36.0 1.004 1.3** 5.9 80.3 45.0
    Y 1 5.8 77.5 1.011 30.6 53.4 201.5 140.3
    4 5.4 201.7 1.021 41.3 59.0 373.8 291.5
    5 7.3 72.7 1.009 35.8 38.9 112.5 104.7
    AA 1 6.8 71.1 1.008 9.8 16.1 183.3 91.2
    4 5.3 101.2 1.011 14.5 16.5 270.4 92.3
    5 5.5 33.3 1.006 7.2 5.2 59.5 26.2
    BB 1 5.9 217.1 1.016 112.1 155.1 345.6 151.7
    4 7.2 47.3 1.004 54.0 66.4 66.4 48.7
    5 5.6 206.0 1.018 192.1 220.1 525.9 220.7
    CC 1 6.7 42.1 1.008 14.0 21.1 42.0 22.3
    4 6.4 162.0 1.010 32.8 155.8 206.8 71.2
    5 6.9 40.3 1.005 11.3 11.8 31.5 15.8
    DD 1 6.2 45.9 1.006 11.8 17.2 53.2 11.5
    4 7.5 71.1 1.007 12.8 10.9 59.2 14.0
    5 7.1 133.9 1.010 7.8 11.5 101.3 26.7
    DDD 1 5.3 160.9 1.018 129.1 586.5 2766.0 2285.4
    4 6.2 139.6 1.014 38.0 230.9 1164.2 1397.7
    5 6.9 73.1 1.007 56.4 452.1 1010.8 1054.1
    ‡Indicates that the specimen validity criteria marked was not acceptable.
    *Indicates that the ion ratio criteria were not met.
    **Indicates that the value is below our established LOD/LOQ of 5 ng/mL and should be interpreted as a negative result.
  • TABLE 6
    Sample Validity and Urine Results Summary at 40 mg/day
    (all metabolite data reported in ng/mL).
    S-Methyl
    Hydroxy- S-Methyl Hydroxy
    Creatinine Specific Lurasidone Lurasidone Lurasidone
    pH (mg/dL) Gravity Lurasidone (M8/M9) (M21) (M22)
    Average 6.50 129.27 1.01 44.23 91.90 407.47 306.08
    Standard 0.92 80.21 0.005 39.43 126.81 529.54 480.90
    Deviation
    n 33
    Maximum 8.40 305.70 1.02 192.10 586.50 2766.00 2285.40
    Value
    Median 6.70 101.00 1.01 33.10 50.90 252.60 136.30
    Value
    Minimum 5.10 33.30 1.00 7.20 5.20 31.50 11.50
    Value

    Samples that were deemed invalid based on pH and/or specific gravity (n=3) were not included in calculations. Any drug/metabolite concentration that was less than the LOD/LOQ (5 ng/m L) as noted in Table 5 was also excluded from the calculations.
    • Example 4
  • The urine of 2 patients who was prescribed 60 mg of Latuda® (lurasidone) was tested for compliance over 5 days (Table 7). The preponderance of M8/M9, M21, and M22 in the urine as the major metabolic urine compounds is shown in Table 7. Assuming 6 opportunities to determine the patient to be either positive or negative for Latuda® dosing, the use of M8/M9, M21, and M22 resulted in 100% correct identification of those taking the prescribed medicine. The data in Table 8 demonstrate the “normal” nature of the sample validity criteria (i.e., pH, specific gravity, and creatinine). Without the M8/M9, M21, or M22 metabolites, still 100% were determined to be positive solely by the parent compound lurasidone. Thus, use of M8/M9, M21, and M22 as a urine biomarker at this dose does not appear to add additional value to compliance monitoring for Latuda®.
  • TABLE 7
    Test Results from Patients Prescribed 60 mg/day Latuda ® (all metabolite
    data reported in ng/mL).
    S-Methyl
    Hydroxy- S-Methyl Hydroxy
    Creatinine Specific Lurasidone Lurasidone Lurasidone
    Subject Day pH (mg/dL) Gravity Lurasidone (M8/M9) (M21) (M22)
    FF 1 7.5 80.1 1.008 15.6 6.3 31.9 19.2
    4 5.4 84.1 1.008 25.3 31.5 104.5 76.7
    5 5.8 282.6 1.020 50.5 93.5 324.0 248.6
    GG 1 5.6 37.2 1.010 16.3 24.6 112.5 85.0
    4 5.2 122.1 1.015 36.8 50.1 260.3 199.8
    5 5.8 151.0 1.013 37.3 55.3 279.1 266.7
    ‡Indicates that the specimen validity criteria marked was not acceptable.
    *Indicates that the ion ratio criteria were not met.
    **Indicates that the value is below our established LOD/LOQ of 5 ng/mL and should be interpreted as a negative result.
  • TABLE 8
    Sample Validity and Urine Results Summary at 60 mg/day (all metabolite
    data reported in ng/mL).
    S-Methyl
    Hydroxy- S-Methyl Hydroxy
    Creatinine Specific Lurasidone Lurasidone Lurasidone
    pH (mg/dL) Gravity Lurasidone (M8/M9) (M21) (M22)
    Average 5.88 126.18 1.01 30.30 43.55 185.38 149.33
    Standard 0.75 78.43 0.004 12.49 27.59 107.25 93.56
    Deviation
    n 6
    Maximum 7.50 282.60 1.02 50.50 93.50 324.00 266.70
    Value
    Median 5.70 103.10 1.01 31.05 40.80 186.40 142.40
    Value
    Minimum 5.20 37.20 1.01 15.60 6.30 31.90 19.20
    Value
    • Example 5
  • The urine of 15 patients who were prescribed 80 mg of Latuda® (lurasidone) was tested for compliance over 5 days (Table 9). The preponderance of M8/M9, M21, and M22 in the urine as the major metabolic urine compounds is clearly demonstrated in Table 5. Assuming 45 opportunities to determine the patient to be either positive or negative for Latuda® dosing, the use of M8/M9, M21, and M22 resulted in ˜96% correct identification of those taking the prescribed medicine. The data in Table 10 demonstrate the “normal” nature of the sample validity criteria (i.e., pH, specific gravity, and creatinine). Without the M8/M9, M21, or M22 metabolites, only ˜93% were determined to be positive solely by the parent compound lurasidone. Thus, use of M8/M9, M21, and M22 as a urine biomarker at this dose adds value to compliance monitoring for Latuda®.
  • TABLE 9
    Test Results from Patients Prescribed 80 mg/day Latuda ® (all metabolite
    data reported in ng/mL).
    S-Methyl
    Hydroxy- S-Methyl Hydroxy
    Creatinine Specific Lurasidone Lurasidone Lurasidone
    Subject Day pH (mg/dL) Gravity Lurasidone (M8/M9) (M21) (M22)
    HH 1 6.2 127.3 1.016 138.5 400.4 1839.9 831.6
    4 6.3 205.1 1.013 83.8 192.9 1954.6 805.5
    5 7.6 87.4 1.008 67.6 118.0 555.0 388.1
    II 1 5.5 102.7 1.013 147.1 258.8 1613.9 736.5
    4 5.9 155.9 1.017 144.8 195.5 2289.0 804.5
    5 7.4 148.7 1.012 112.7 117.2 1475.2 773.7
    JJ 1 6.1 218.7 1.011 57.3 29.9 309.4 129.2
    4 6.7 281.9 1.009 69.6 142.8 1163.8 909.3
    5 5.9 315.9 1.012 100.6 243.3 1615.3 1134.8
    KK 1 5.3 147.4 1.013 152.8 343.3 1274.9 795.7
    4 6.1 130.9 1.011 83.3 135.3 662.1 575.0
    5 5.0 290.2 1.020 72.4 121.0 1379.3 773.0
    LL 1 5.7 247.7 1.013 556.6 897.1 7993.3 2285.6
    4 5.3 218.2 1.016 503.8 695.0 6790.7 1949.3
    5 6.5 160.8 1.009 264.0 276.7 4321.1 1709.6
    MM 1 6.9 191.0 1.011 175.2 377.1 2054.5 1152.6
    4 7.1 158.7 1.010 96.4 152.9 836.2 679.7
    5 6.1 301.5 1.015 116.3 162.6 1663.1 1009.9
    NN 1 6.9 74.4 1.007 52.6 66.3 329.0 91.8
    4 7.7 90.8 1.007 43.7 54.6 293.8 102.0
    5 7.7 88.7 1.006 38.9 53.2 288.5 107.9
    VV 1 8.7 124.2 1.009 23.0 58.5 210.5 171.0
    4 7.9 203.3 1.011 0.1** 0.0** 0.0** 0.0**
    5 6.6 249.6 1.010 36.7 146.4 448.8 387.6
    WW 1 8.1 230.7 1.008 40.5 272.2 1014.4 2176.4
    4 5.3 171.3 1.016 162.5 202.2 1214.3 1053.3
    5 7.1 127.5 1.010 48.3 80.5 534.6 886.9
    EEE 1 7.0 17.9 1.002 10.1 18.2 29.0 15.1
    4 5.5 36.3 1.003 14.5 15.4 32.6 28.2
    5 5.7 124.7 1.007 41.0 42.2 69.8 88.4
    FFF 1 7.0 137.4 1.011 210.7 380.1 1469.3 564.9
    4 5.5 148.1 1.014 70.4 82.1 913.3 349.3
    5 5.5 20.9 1.003 16.1 11.8 104.9 54.4
    HHH 1 6.4 285.5 1.010 145.2 290.9 8565.0 6401.5
    4 6.5 235.3 1.012 298.3 837.0 9603.9 5431.7
    5 6.6 222.5 1.013 539.5 887.1 9292.5 4613.8
    JJJ 1 6.9 83.2 1.007 59.5 88.0 443.6 320.0
    4 5.5 187.7 1.014 35.9 14.3 199.5 84.7
    5 7.3 141.1 1.012 69.5 71.2 1236.1 398.7
    KKK 1 7.3 355.5 1.009 4.8** 3.3* ** 48.4 40.7
    4 6.6 18.3 1.003 52.0 147.2 462.7 476.7
    5 7.4 43.7 1.007 22.9 30.3 142.1 243.7
    LLL 1 5.7 299.7 1.020 0.0** 0.0** 0.0** 0.0**
    4 5.5 248.0 1.019 32.9 246.2 915.3 1120.9
    5 5.6 306.3 1.023 43.5 295.6 1277.9 1502.4
    ‡Indicates that the specimen validity criteria marked was not acceptable.
    *Indicates that the ion ratio criteria were not met.
    **Indicates that the value is below our established LOD/LOQ of 5 ng/mL and should be interpreted as a negative result.
  • TABLE 10
    Sample Validity and Urine Results Summary at 80 mg/day (all metabolite
    data reported in ng/mL).
    S-Methyl
    Hydroxy- S-Methyl Hydroxy
    Creatinine Specific Lurasidone Lurasidone Lurasidone
    pH (mg/dL) Gravity Lurasidone (M8/M9) (M21) (M22)
    Average 6.47 172.50 1.01 120.26 220.27 1835.61 1026.87
    Standard 0.88 87.12 0.005 131.50 226.06 2550.78 1359.91
    Deviation
    n 45
    Maximum 8.70 355.50 1.02 556.60 897.10 9603.90 6401.50
    Value
    Median 6.50 158.70 1.01 70.00 146.80 1014.40 736.50
    Value
    Minimum 5.00 17.90 1.00 10.10 11.80 29.00 15.10
    Value

    Any drug/metabolite concentration that was less than the LOD/LOQ (5 ng/mL) as noted in Table 5 was also excluded from the calculations.
    • Example 6
  • The urine of 1 patient who was prescribed 100 mg of Latuda® (lurasidone) was tested for compliance over 5 days (Table 11). The preponderance of M8/M9, M21, and M22 in the urine as the major metabolic urine compounds is clearly demonstrated in Table 11. Assuming 3 opportunities to determine the patient to be either positive or negative for Latuda® dosing, the use of M8/M9, M21, and M22 resulted in 100% correct identification of those taking the prescribed medicine. The data in Table 12 demonstrate the “normal” nature of the sample validity criteria (i.e., pH, specific gravity, and creatinine). Without the M8/M9, M21, or M22 metabolites, still 100% were determined to be positive solely by the parent compound lurasidone.
  • TABLE 11
    Test Results from Patients Prescribed 100 mg/day Latuda ® (all metabolite
    data reported in ng/mL).
    S-Methyl
    Hydroxy- S-Methyl Hydroxy
    Creatinine Specific Lurasidone Lurasidone Lurasidone
    Subject Day pH (mg/dL) Gravity Lurasidone (M8/M9) (M21) (M22)
    OO 1 5.6 172.4 1.014 94.9 188.4 1404.7 271.2
    4 5.9 239.9 1.012 62.5 186.4 1599.4 456.6
    5 6.0 141.9 1.011 64.5 153.9 1032.3 253.8
    ‡Indicates that the specimen validity criteria marked was not acceptable.
    *Indicates that the ion ratio criteria were not met.
    **Indicates that the value is below our established LOD/LOQ of 5 ng/mL and should be interpreted as a negative result.
  • TABLE 12
    Sample Validity and Urine Results Summary at 100 mg/day (all metabolite
    data reported in ng/mL).
    S-Methyl
    Hydroxy- S-Methyl Hydroxy
    Creatinine Specific Lurasidone Lurasidone Lurasidone
    pH (mg/dL) Gravity Lurasidone (M8/M9) (M21) (M22)
    Average 5.83 184.73 1.01 73.97 176.23 1345.47 327.20
    Standard 0.17 40.95 0.00 14.82 15.81 235.28 91.77
    Deviation
    n
    3
    Maximum 6.00 239.90 1.01 94.90 188.40 1599.40 456.60
    Value
    Median 5.90 172.40 1.01 64.50 186.40 1404.70 271.20
    Value
    Minimum 5.60 141.90 1.01 62.50 153.90 1032.30 253.80
    Value
    • Example 7
  • The urine of 6 patients who were prescribed 120 mg of Latuda® (lurasidone) was tested for compliance over 5 days (Table 13). The preponderance of M8/M9, M21, and M22 in the urine as the major metabolic urine compounds is clearly demonstrated in Table 13. Assuming 18 opportunities to determine the patient to be either positive or negative for Latuda® dosing, the use of M8/M9, M21, and M22 resulted in 100% correct identification of those taking the prescribed medicine. The data in Table 14 demonstrate the “normal” nature of the sample validity criteria (i.e., pH, specific gravity, and creatinine). Without the M8/M9, M21, or M22 metabolites, 100% were still determined to be positive solely by the parent compound lurasidone.
  • TABLE 13
    Test Results from Patients Prescribed 120 mg/day Latuda ® (all metabolite
    S-Methyl
    Hydroxy- S-Methyl Hydroxy
    Creatinine Specific Lurasidone Lurasidone Lurasidone
    Subject Day pH (mg/dL) Gravity Lurasidone (M8/M9) (M21) (M22)
    PP 1 7.6 90.6 1.008 102.7 185.5 506.6 315.2
    4 8.0 106.5 1.007 87.3 89.0 359.6 296.1
    5 7.7 57.1 1.008 59.1 63.4 491.2 436.1
    QQ 1 6.7 13.9‡ 1.002 21.7 17.1 150.3 50.4
    4 6.7 26.5 1.001‡ 23.7 17.4 207.0 75.2
    5 6.1 129.7 1.007 61.6 56.7 708.6 273.6
    RR 1 6.1 230.4 1.019 83.9 329.9 2127.9 1608.2
    4 6.9 141.5 1.008 46.4 269.8 2039.4 1590.1
    5 6.7 149.7 1.010 63.3 313.7 2507.7 1697.6
    SS 1 7.7 24.5 1.003 126.2 130.2 413.7 262.9
    4 7.4 37.9 1.004 150.7 124.9 731.4 340.2
    5 7.1 69.1 1.009 251.7 208.1 1588.9 620.5
    UU 1 5.3 180.6 1.016 23.4 170.9 425.0 305.7
    4 5.2 217.1 1.018 27.5 23.1 202.4 207.5
    5 5.5 110.7 1.013 12.4 7.8 81.6 75.7
    GGG 1 6.3 40.2 1.002 148.7 162.4 1094.9 774.5
    4 6.0 303.7 1.014 260.1 586.3 6580.7 4807.4
    5 6.6 16.5‡ 1.001‡ 57.2 50.3 244.9 224.4
    ‡Indicates that the specimen validity criteria marked was not acceptable.
    *Indicates that the ion ratio criteria were not met.
    **Indicates that the value is below our established LOD/LOQ of 5 ng/mL and should be interpreted as a negative result.
  • TABLE 14
    Sample Validity and Urine Results Summary at 120 mg/day (all metabolite
    data reported in ng/mL).
    S-Methyl
    Hydroxy- S-Methyl Hydroxy
    Creatinine Specific Lurasidone Lurasidone Lurasidone
    pH (mg/dL) Gravity Lurasidone (M8/M9) (M21) (M22)
    Average 6.64 125.95 1.01 95.42 171.18 1250.62 853.86
    Standard 0.87 77.40 0.01 73.60 145.10 1562.57 1151.33
    Deviation
    n 16
    Maximum 8.00 303.70 1.02 260.10 586.30 6580.70 4807.40
    Value
    Median 6.70 110.70 1.01 73.60 146.30 607.60 327.70
    Value
    Minimum 5.20 24.50 1.00 12.40 7.80 81.60 50.40
    Value

    Samples that were deemed invalid based on pH and/or specific gravity (n=2) were not included in calculations.
  • These examples demonstrate that lurasidone metabolites M8/M9, M21, and M22 provide a greater level of sensitivity and consistency among subjects on lurasidone therapy than afforded by the parent drug alone, particularly at lower doses, and therefore provide superior urine analytes for evaluation of a subject's compliance with a lurasidone therapeutic regimen.
  • From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

Claims (13)

I/We claim:
1. A method for identifying a subject as non-compliant with a prescribed lurasidone therapy, the method comprising:
obtaining a fluid sample from a subject who has been prescribed lurasidone therapy;
determining a level of M8/M9, M21, and/or M22 in the fluid sample; and
identifying the subject as adherent to the prescribed lurasidone therapy if the fluid sample contains M8/M9, M21, and/or M22 above a threshold level but non-adherent if the fluid sample contains no M8/M9, M21, and/or M22 or an amount of M8/M9, M21, and/or M22 below a threshold level.
2. The method of claim 1 further comprising counseling the subject on dangers of non-adherence to lurasidone therapy if the subject is identified as non-adherent.
3. The method of claim 1, wherein the threshold level is a minimum detectable amount of M8/M9, M21, and/or M22.
4. The method of claim 1, wherein the threshold level is about 50 ng/mL.
5. The method of claim 1, wherein the threshold level is about 5 ng/mL.
6. The method of claim 1, wherein the fluid sample is a urine sample.
7. A method of determining compliance with lurasidone therapy in a subject, the method comprising:
obtaining a fluid sample from the subject;
analyzing the fluid sample for presence or absence of an analyte; and
identifying the subject as compliant if the analyte is present in the fluid sample.
8. The method of claim 7, wherein the analyte comprises lurasidone and/or a lurasidone metabolite.
9. The method of claim 7, wherein the analyte is selected from the group consisting of M5, M10, M11, M11 Gluc, ID-20221, ID-20222, M8/M9, M21, and M22.
10. The method of claim 8, wherein the analyte comprises M8/M9, M21, and/or M22.
11. The method of claim 7, wherein the analyte is considered present in the fluid sample if the analyte is detected above a threshold value.
12. The method of claim 11, wherein the threshold value is about 50 ng/mL.
13. The method of claim 11, wherein the threshold value is about 5 ng/mL.
US15/469,021 2013-12-12 2017-03-24 Methods of monitoring adherence to lurasidone therapy Abandoned US20170192025A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/469,021 US20170192025A1 (en) 2013-12-12 2017-03-24 Methods of monitoring adherence to lurasidone therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361915070P 2013-12-12 2013-12-12
US201462035821P 2014-08-11 2014-08-11
US14/567,935 US9606132B2 (en) 2013-12-12 2014-12-11 Methods of monitoring adherence to lurasidone therapy
US15/469,021 US20170192025A1 (en) 2013-12-12 2017-03-24 Methods of monitoring adherence to lurasidone therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/567,935 Continuation US9606132B2 (en) 2013-12-12 2014-12-11 Methods of monitoring adherence to lurasidone therapy

Publications (1)

Publication Number Publication Date
US20170192025A1 true US20170192025A1 (en) 2017-07-06

Family

ID=53368111

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/567,935 Expired - Fee Related US9606132B2 (en) 2013-12-12 2014-12-11 Methods of monitoring adherence to lurasidone therapy
US15/469,021 Abandoned US20170192025A1 (en) 2013-12-12 2017-03-24 Methods of monitoring adherence to lurasidone therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/567,935 Expired - Fee Related US9606132B2 (en) 2013-12-12 2014-12-11 Methods of monitoring adherence to lurasidone therapy

Country Status (1)

Country Link
US (2) US9606132B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397424A (en) * 2016-03-30 2017-02-15 北京万全德众医药生物技术有限公司 Preparation method of lurasidone hydrochloride oxidation impurities
WO2018023009A1 (en) * 2016-07-29 2018-02-01 Concert Pharmaceuticals, Inc. Deuterated lurasidone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158492A2 (en) * 2011-05-13 2012-11-22 Dainippon Sumitomo Pharma Co., Ltd. Treatment and management of cns disorders
US9580414B2 (en) * 2012-07-18 2017-02-28 Shasun Pharmaceuticals Limited Salts and hydrates of antipsychotics

Also Published As

Publication number Publication date
US20150168431A1 (en) 2015-06-18
US9606132B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
Han et al. Profiling novel metabolic biomarkers for Parkinson's disease using in‐depth metabolomic analysis
Guidry et al. Measurement of total and free urinary phenol and paraben concentrations over the course of pregnancy: assessing reliability and contamination of specimens in the Norwegian Mother and Child Cohort Study
Cribbs et al. Metabolomics of bronchoalveolar lavage differentiate healthy HIV-1-infected subjects from controls
EP3019624B1 (en) Biomarkers of autism spectrum disorder
Joensen et al. Urinary excretion of phenols, parabens and benzophenones in young men: Associations to reproductive hormones and semen quality are modified by mutations in the Filaggrin gene
US20090318556A1 (en) Biomarkers for detecting radiation exposure: methods and uses thereof
Won et al. Association of current phthalate exposure with neurobehavioral development in a national sample
Gwiazda et al. Detection of depleted uranium in urine of veterans from the 1991 Gulf War
Weikert et al. B vitamin plasma levels and the risk of ischemic stroke and transient ischemic attack in a German cohort
Grison et al. The metabolomic approach identifies a biological signature of low-dose chronic exposure to cesium 137
Wang et al. Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study
Chew‐Harris et al. Removal of body surface area normalisation improves raw‐measured glomerular filtration rate estimation by the Chronic Kidney Disease Epidemiology Collaboration equation and drug dosing in the obese
Baima et al. Macro and trace elements signature of periodontitis in saliva: A systematic review with quality assessment of ionomics studies
Ibrahim et al. The health-related quality of life among pre-diabetics and its association with body mass index and physical activity in a semi-urban community in Malaysia-a cross sectional study
US20170192025A1 (en) Methods of monitoring adherence to lurasidone therapy
Maze et al. Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand
US20170299574A1 (en) Methods of monitoring for adherence to aripiprazole therapy
Sridharan et al. Comparison of energy estimates in chronic kidney disease using doubly‐labelled water
Lu et al. Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients
Hoeke et al. Monitoring of drug intake during pregnancy by questionnaires and LC‐MS/MS drug urine screening: evaluation of both monitoring methods
Tomioka et al. Increased risk of lung cancer associated with occupational exposure to benzidine and/or beta-naphthylamine
Tusiewicz et al. A fatal case involving the highest ever reported 4‐CMC concentration
Eyer et al. Risk assessment of severe tricyclic antidepressant overdose
WO2019204283A1 (en) Methods of monitoring, treating, and preventing renal inflammation associated with kidney transplantation
Kim et al. Morning spot urine glucose-to-creatinine ratios predict overnight urinary glucose excretion in patients with type 2 diabetes

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION